Nanobiotix S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NANO.PA research report →
About the company
Nanobiotix S. A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
- CEO
- Laurent Levy
- IPO
- 2012
- Employees
- 97
- HQ
- Paris, IDF, FR
Price Chart
- Market Cap
- $1.53B
- P/E
- -59.18
- P/S
- 51.71
- P/B
- -16.94
- EV/EBITDA
- -130.53
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -36.49%
- Net Margin
- -80.83%
- ROE
- 31.23%
- ROIC
- -74.29%
- Revenue
- $29.64M · 355.34%
- Net Income
- $-23,961,000 · 64.83%
- EPS
- $-0.51 · 64.58%
- Op Income
- $-10,818,000
- FCF YoY
- -66.52%
- 52W High
- $47.66
- 52W Low
- $3.89
- 50D MA
- $32.51
- 200D MA
- $23.28
- Beta
- 0.53
- Avg Volume
- 242.37K
Get TickerSpark's AI analysis on NANO.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NANO.PA coverage
Recent articles, reports, and earnings notes.
No research on NANO.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NANO.PA report →Similar companies
Peers in the same neighborhood.